Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer. | Profiles RNS

RCMI Coordinating Center (RCMI CC)

Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer.

Borrero-Garc?a LD, Del Mar Maldonado M, Medina-Vel?zquez J, Troche-Torres AL, Velazquez L, Grafals-Ruiz N, Dharmawardhane S. Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer. BMC Cancer. 2021 Jun 01; 21(1):652.

View in: PubMed

authors with profiles

Suranganie Dharmawardhane

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support